Fifth Third Bancorp Has $541.38 Million Holdings in AbbVie Inc. $ABBV
I'm LongbridgeAI, I can summarize articles.Fifth Third Bancorp reduced its AbbVie holdings by 2.1% in Q2, retaining 2.15 million shares valued at $541.38 million. Meanwhile, other institutions like Ranch Capital and Mission Wealth increased their stakes. Analysts maintain a 'Moderate Buy' consensus with an average target of $275.95. Recent news includes positive lung cancer data and aesthetics pipeline updates, alongside neutral earnings reports and uncertainty from a terminated schizophrenia study.
Fifth Third Bancorp cut its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 2.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,151,394 shares of the company's stock after selling 46,500 shares during the period. AbbVie makes up 0.9% of Fifth Third Bancorp's investment portfolio, making the stock its 17th biggest holding. Fifth Third Bancorp owned 0.12% of AbbVie worth $541,377,000 as of its most recent SEC filing.
- MarketBeat Week in Review – 08/03 - 08/07
Several other hedge funds have also recently bought and sold shares of ABBV. Ranch Capital Advisors Inc. lifted its stake in shares of AbbVie by 37.0% in the first quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company's stock worth $3,238,000 after buying an additional 4,017 shares during the last quarter. Capital Advisors Inc. OK boosted its holdings in shares of AbbVie by 11.2% during the 2nd quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company's stock worth $112,516,000 after buying an additional 45,132 shares during the period. Wedge Capital Management L L P NC grew its stake in AbbVie by 7.5% in the 2nd quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company's stock valued at $33,865,000 after buying an additional 9,380 shares during the last quarter. Mission Wealth Management LP grew its stake in AbbVie by 119.1% in the 2nd quarter. Mission Wealth Management LP now owns 69,052 shares of the company's stock valued at $17,376,000 after buying an additional 37,531 shares during the last quarter. Finally, Axecap Investments LLC raised its holdings in AbbVie by 713.2% in the 4th quarter. Axecap Investments LLC now owns 16,320 shares of the company's stock worth $3,729,000 after acquiring an additional 14,313 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
ABBV has been the subject of a number of research analyst reports. Sanford C. Bernstein reissued a "market perform" rating on shares of AbbVie in a research report on Tuesday, June 23rd. Morgan Stanley reiterated an "overweight" rating and issued a $296.00 price objective on shares of AbbVie in a research note on Monday, August 3rd. HSBC reissued a "buy" rating and set a $300.00 price objective on shares of AbbVie in a research report on Monday, July 6th. JPMorgan Chase & Co. increased their target price on AbbVie from $260.00 to $280.00 and gave the company an "overweight" rating in a research note on Thursday, July 9th. Finally, Wells Fargo & Company raised their target price on AbbVie from $295.00 to $300.00 and gave the company an "overweight" rating in a report on Monday, August 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $275.95.
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
View Our Latest Analysis on ABBV
AbbVie News Summary
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: New lung-cancer data supports AbbVie’s long-term growth strategy. At the 2026 World Conference on Lung Cancer, AbbVie presented clinical, translational and real-world data for investigational programs including ABBV-1480, telisotuzumab adizutecan and ABBV-706 across non-small cell and small cell lung cancer. The updates highlight potential future oncology revenue sources beyond the company’s established immunology portfolio. AbbVie WCLC 2026 announcement
- Positive Sentiment: AbbVie is broadening its aesthetics pipeline. The company has initiated a Phase 2 study evaluating a treatment for forehead lines, adding another potential product to its aesthetics franchise and reinforcing efforts to diversify growth. AbbVie aesthetics pipeline update
- Neutral Sentiment: AbbVie’s relatively low market correlation reflects its defensive pharmaceutical revenue base. Investor performance is driven more by product demand, reimbursement and payer dynamics than by broad equity-market movements. This may help explain the stock’s resilience, but the article does not identify a new earnings catalyst. What Moves AbbVie Stock
- Neutral Sentiment: AbbVie recently reported quarterly EPS and revenue above consensus, with revenue rising 10.2% year over year, and guided to third-quarter EPS of $3.84–$3.88. Analysts’ average price target of $275.73 remains above the current trading level, although the stock’s elevated valuation raises expectations. AbbVie stock and earnings information
- Negative Sentiment: An early end to a long-term emraclidine schizophrenia study introduces uncertainty. Investors may question the implications for AbbVie’s neuroscience pipeline and the program’s development prospects until the company provides additional details. AbbVie emraclidine study update
- Negative Sentiment: An executive vice president sold approximately $8.18 million of ABBV shares, reducing his position by about 30.5%. The sale may weigh modestly on sentiment, although insider transactions can reflect personal financial planning rather than a change in business outlook. AbbVie insider sale
AbbVie Trading Up 0.2%
- AbbVie Quietly Solved Its Biggest Problem—Now What?
ABBV stock opened at $265.62 on Monday. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $267.47. The firm has a market cap of $469.29 billion, a P/E ratio of 75.03, a P/E/G ratio of 0.88 and a beta of 0.30. The business's 50 day moving average is $248.48 and its 200-day moving average is $227.50.
AbbVie (NYSE:ABBV - Get Free Report) last posted its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.AbbVie's revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the company earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Sell-side analysts forecast that AbbVie Inc. will post 14.06 EPS for the current year.
AbbVie Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.6%. The ex-dividend date was Wednesday, July 15th. AbbVie's payout ratio is currently 195.48%.
Insider Activity at AbbVie
In other news, EVP Nicholas Donoghoe sold 32,710 shares of the company's stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company's stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.06% of the company's stock.
AbbVie Company Profile
(Free Report)AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.
Recommended Stories
- Five stocks we like better than AbbVie
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab's Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Add As Preferred Source
Should You Invest $1,000 in AbbVie Right Now?
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here